Introducing Genetic Tolerance Through HLA Gene Editing: Evaluating the Preclinical Data & Regulatory Feedback

Time: 2:45 pm
day: Conference Day Two


  • Identifying antigen-specific HLA gene-editing targets with bioinformatics and novel assays
  • Editing the HLA gene without immunosuppression or rejection
  • Reviewing the preclinical data and FDA feedback for Rheumagen’s lead indication of treatment-resistant rheumatoid arthritis